CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
38.93
-1.26 (-3.14%)
At close: Nov 19, 2026, 4:00 PM EST
38.75
-0.18 (-0.46%)
After-hours: Nov 19, 2026, 5:37 PM EST
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $12.67M in the quarter ending September 30, 2026, with 1,325.08% growth. This brings the company's total for the last twelve months to $25.17M, down -34.34% year-over-year. In the year 2025, CRISPR Therapeutics AG had annual revenue of $3.51M, down -90.59%. That makes CRISPR Therapeutics AG the 32,492nd largest company in the world by revenue and 4,264th in the United States.
Revenue (ttm)
$25.17M
Revenue Growth
-34.34%
P/S Ratio
153.76
Revenue / Employee
$64,051
Employees
393
Market Cap
3.78B
Revenue by Segment
- Collaboration 35.00M 93.8%
- Grant 2.31M 6.2%
Fiscal year ended Dec 31, 2024 See the full CRISPR Therapeutics AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.51M | -33.80M | -90.59% |
| Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
| Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
| Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
| Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
| Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
| Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
| Dec 31, 2018 | 3.12M | -37.87M | -92.38% |
| Dec 31, 2017 | 41.00M | 35.83M | 693.90% |
| Dec 31, 2016 | 5.16M | 4.92M | 1,990.69% |
| Dec 31, 2015 | 247.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 682.20M |
| Arcutis Biotherapeutics | 508.68M |
| Iovance Biotherapeutics | 378.98M |
| AbCellera Biologics | 67.85M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
CRSP News
- 2 days ago - CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference - Transcripts
- 9 days ago - CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 days ago - CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026 - GlobeNewsWire
- 11 days ago - CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases - GlobeNewsWire
- 15 days ago - CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 15 days ago - Crispr Therapeutics price target lowered to $80 from $81 at BofA - TheFly
- 15 days ago - Crispr Therapeutics price target raised to $90 from $88 at Citi - TheFly
- 15 days ago - Crispr Therapeutics price target lowered to $70 from $75 at Wells Fargo - TheFly